M
M Mafham
Researcher at University of Oxford
Publications - 37
Citations - 7997
M Mafham is an academic researcher from University of Oxford. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 12, co-authored 25 publications receiving 6370 citations. Previous affiliations of M Mafham include Clinical Trial Service Unit.
Papers
More filters
Journal ArticleDOI
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Journal ArticleDOI
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Peter Horby,M Mafham,Louise Linsell,Jennifer L Bell,Natalie Staplin,Jonathan Emberson,Martin Wiselka,Andrew Ustianowski,E Elmahi,B Prudon,Tony Whitehouse,Timothy Felton,John Williams,J Faccenda,Jonathan Underwood,J K Baillie,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Wei Shen Lim,Alan A Montgomery,Kathy Rowan,Joel Tarning,James A Watson,Nicholas J. White,Edmund Juszczak,Richard Haynes,Martin J Landray +28 more
TL;DR: In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death.
Journal ArticleDOI
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter Horby,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Jonathan Emberson,Adrian Palfreeman,Jason Raw,E Elmahi,B Prudon,Christopher A Green,Simon Carley,David Chadwick,Matthew N. Davies,Matt P. Wise,J Kenneth Baillie,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jefferey,Wei Shen Lim,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.
Journal ArticleDOI
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter Horby,Marion K Campbell,Enti Spata,Jonathan Emberson,Natalie Staplin,Guilherme Pessoa-Amorim,Leon Peto,Martin Wiselka,L Wiffen,Simon Tiberi,B Caplin,C Wroe,Carole Green,Paul Hine,B Prudon,T George,A Wight,J K Baillie,Buddha Basnyat,Maya H Buch,Lucy C Chappell,Jeremy N. Day,Saul N. Faust,Raph L. Hamers,Thomas Jaki,Edmund Juszczak,Katie Jeffery,Wei Shen Lim,Alan A Montgomery,Andrew D Mumford,Kathy Rowan,G Thwaites,M Mafham,Richard Haynes,Martin J Landray +34 more
TL;DR: In this paper, the authors evaluated the effects ofcilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation, and found that the drug improved survival and other clinical outcomes.
Journal ArticleDOI
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Martin J Landray,Peter Horby,Jonathan Emberson,Natalie Staplin,Enti Spata,Guilherme Pessoa-Amorim,Leon Peto,M Mafham,Richard Haynes +8 more
TL;DR: In this article, the authors evaluated the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19 and found no significant difference in 28-day mortality between the two groups.